Pilot Study: Effectiveness of Different Kefir Formulations on Symptoms of Functional Constipation in Chilean Adults. (KEF-CON)
Evaluation of the Efficacy of Different Homemade Kefir Formulations in Improving Symptoms of Functional Chronic Constipation in Chilean Adults.
Functional chronic constipation is a common digestive disorder in Chilean adults. It causes infrequent or difficult bowel movements, abdominal discomfort and a feeling of incomplete evacuation, and it can impair quality of life. Kefir is a fermented milk made with grains that contain lactic acid bacteria and yeasts. It has been proposed as a dietary option to relieve constipation, but its effects may depend on how it is prepared.
The purpose of this study is to evaluate whether daily intake of two homemade kefir formulations, one made with whole milk and one made with skim milk, improves constipation symptoms and quality of life in adults with functional chronic constipation, compared with dietary counseling alone.
Thirty adults of both sexes diagnosed with functional chronic constipation according to the Rome IV criteria will be randomly assigned to one of three groups (10 per group):
Whole-milk kefir (KLE) Skim-milk kefir (KLD) Control group receiving nutritional counseling based on the Chilean Dietary Guidelines only
Participants in the kefir groups will follow a gradual dose increase (50, 100, 150 and up to 200 mL/day) for 4 weeks. Both kefir formulations will be prepared under standardized conditions (6% grain inoculation, 48-hour fermentation) and characterized for their nutritional, microbiological and sensory properties before the trial.
The primary outcome will be constipation-specific quality of life, measured with the PAC-QOL questionnaire. Secondary outcomes will include constipation symptoms (Rome IV criteria), stool consistency (Bristol Stool Form Scale) and generic health-related quality of life (EQ-5D). Dietary intake (24-hour recall and food frequency questionnaire) and physical activity (GPAQ) will be recorded as potential confounders. All assessments will be done before and after the intervention.
The researchers expect that participants who drink kefir will improve their constipation symptoms and quality of life more than those who receive counseling only. They also expect a greater improvement with the whole-milk kefir
Visão geral do estudo
Status
Status
Condições
Condições
Intervenção / Tratamento
Intervenção / Tratamento
Tipo de estudo
Tipo de estudo
Inscrição (Estimado)
Inscrição
Estágio
Estágio
- Não aplicável
Contactos e Locais
Contato de estudo
Contato de estudo
- Nome: CECILIA A SEPULVEDA, MAGISTER EN NUTRICIÓN
- Número de telefone: +56998921007
- E-mail: CECILIA.SEPULVEDA@UMAYOR.CL
Estude backup de contato
- Nome: ANNETTE N TROMBERT, DOCTOR EN MICROBIOLOGIA
- Número de telefone: 562333281424
- E-mail: ANNETTE.TROMBERT@UMAYOR.CL
Locais de estudo
-
-
Huechuraba
-
Santiago, Huechuraba, Chile, 7750000
- Recrutamento
- Universidad Mayor
-
Contato:
- CECILIA SEPULVEDA A SEPULVEDA, MAGISTER
- Número de telefone: 56998921007
- E-mail: CECILIA.SEPULVEDA@UMAYOR.CL
-
Contato:
- ANNETTE N TROMBERT, DOCTOR EN MICROBIOLOGIA
- Número de telefone: 56223281424
- E-mail: ANNETTE.TROMBERT@UMAYOR.CL
-
Investigador principal:
- CECILIA A SEPULVEDA, MAGISTER EN NUTRICION
-
-
Critérios de participação
Critérios de elegibilidade
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Descrição
Inclusion Criteria:
- Adults aged 18 to 55 years.
- Meet the Rome IV criteria for functional constipation, assessed using the Rome IV Diagnostic Questionnaire, with or without a previous medical diagnosis of chronic functional constipation. When a prior diagnosis is present, it is recorded as medical history, and the Rome IV criteria are verified independently.
- Member of the Universidad Mayor Huechuraba campus community (students, faculty members, administrative staff, or support personnel).
- No consumption of kefir, probiotics, prebiotics, or fermented dairy products during the 4 weeks prior to enrollment.
- Have access to a home refrigerator and be available to attend weekly product distribution sessions and study assessments.
Exclusion Criteria:
- Secondary constipation (organic, pharmacological, or metabolic) or acute constipation.
- Chronic use of corticosteroids, antispasmodics, nonsteroidal anti-inflammatory drugs (NSAIDs), iron supplements, aluminum-containing antacids, opioids, calcium channel blockers, or immunotherapy.
- Current antibiotic treatment or antibiotic use within the 4 weeks prior to enrollment.
- Lactose intolerance, celiac disease, or cow's milk protein allergy.
- Type 1 or Type 2 diabetes mellitus.
- Hypothyroidism.
- Chronic kidney disease.
- Hypoparathyroidism.
- Hypercalcemia.
- Parkinson's disease.
- History of stroke with residual neurological sequelae.
- HIV infection.
- Immunosuppression of any cause.
- Irritable bowel syndrome.
- Inflammatory bowel disease.
- History of bariatric surgery.
- History of colorectal surgery.
- Pregnancy or lactation.
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Cuidados de suporte
- Alocação: Randomizado
- Modelo Intervencional: Atribuição Paralela
- Mascaramento: Triplo
Número de braços
Armas e Intervenções
Grupo de Participantes / BraçoGrupo de Participantes / Braço |
Intervenção / TratamentoIntervenção / Tratamento |
|---|---|
|
Experimental: Whole Milk Kefir (KLE)
Participants receive homemade kefir prepared with whole milk (6% grain inoculation, 48-hour fermentation), with an escalating daily dose of 50, 100, 150 and 200 mL. In addition to dietary counseling |
Homemade kefir produced by fermenting whole milk with kefir grains (6% inoculation, 48-hour fermentation). Administered orally once daily for 1 month. The dose is escalated every 24 hours during the first 3 days (50 mL on day 1, 100 mL on day 2, 150 mL on day 3), reaching 200 mL/day from day 4, which is maintained until the end of the intervention. Differs from the skim milk formulation in fat content. In addition a dietary couselling Single standardized nutritional counseling session for chronic functional constipation, delivered by a registered dietitian at baseline after randomization, including recommendations on dietary fiber, fluid intake and eating habits. Participants are followed for 1 month. |
|
Experimental: Skim Milk Kefir (KLD)
Participants receive homemade kefir prepared with skim milk (6% grain inoculation, 48-hour fermentation), with an escalating daily dose of 50, 100, 150 and 200 mL. In addition to dietary counseling |
Single standardized nutritional counseling session for chronic functional constipation, delivered by a registered dietitian at baseline after randomization, including recommendations on dietary fiber, fluid intake and eating habits. Participants are followed for 1 month. Participants receive homemade skim milk kefir orally once daily for 1 month, with a dose escalated every 24 hours during the first 3 days (50, 100 and 150 mL) and maintained at 200 mL/day from day 4 until the end of the intervention.In addition a dietary couselling |
|
Comparador Ativo: Dietary Counseling (Control)
Participants receive standardized dietary counseling for chronic functional constipation, without kefir supplementation. |
Single standardized nutritional counseling session for chronic functional constipation, delivered by a registered dietitian at baseline after randomization, including recommendations on dietary fiber, fluid intake and eating habits. Participants are followed for 1 month. |
O que o estudo está medindo?
Medidas de resultados primários
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Change from Baseline in the Number of Rome IV Diagnostic Criteria for Functional Constipation Met at 1 Month
Prazo: Baseline and 1 month (end of intervention)
|
Functional constipation symptoms were assessed with the Rome IV diagnostic criteria. Each participant was scored on six criteria: straining, lumpy or hard stools (Bristol Stool Form Scale types 1-2), sensation of incomplete evacuation, sensation of anorectal obstruction or blockage, and manual maneuvers to facilitate defecation, each present in more than 25% of defecations, plus fewer than 3 spontaneous bowel movements per week. The score ranges from 0 (minimum, no criteria met) to 6 (maximum, all criteria met). Higher scores indicate more severe constipation, which is a worse outcome. At baseline, criteria were assessed according to the Rome IV time requirement (symptoms present during the last 3 months, with onset at least 6 months before diagnosis). At the end of the intervention, they were assessed for the 1-month intervention period. The change from baseline (number of criteria at the end of the intervention minus baseline) was compared between the homemade whole-milk kefir group |
Baseline and 1 month (end of intervention)
|
Medidas de resultados secundários
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Change from Baseline in the Patient Assessment of Constipation Quality of Life (PAC-QOL) Overall Score at 1 Month
Prazo: Baseline and 1 month (end of intervention)
|
Constipation-specific quality of life was assessed with the Patient Assessment of Constipation Quality of Life questionnaire (PAC-QOL). It is a self-administered instrument of 28 items grouped into four subscales: physical discomfort (4 items), psychosocial discomfort (8 items), worries and concerns (11 items) and satisfaction (5 items). Each item is rated on a 5-point Likert scale from 0 to 4. The satisfaction items are reverse-scored. The overall score is the mean of all items, and each subscale score is the mean of its items. Overall and subscale scores range from 0 (minimum) to 4 (maximum). Higher scores indicate worse quality of life. The change from baseline (overall score at the end of the intervention minus baseline) was compared between the homemade whole-milk kefir group, the homemade skim-milk kefir group and the standard dietary counseling group. A negative change indicates improvement in quality of life. |
Baseline and 1 month (end of intervention)
|
|
Change from Baseline in the Number of Bowel Movements per Week, as Recorded in a Self-Report Diary, at 1 Month
Prazo: Baseline and 1 month (end of intervention)
|
Participants recorded each bowel movement in a self-report diary. Weekly bowel movement frequency was calculated as the number of bowel movements per week. The change from baseline (weekly frequency at the end of the intervention minus baseline) was compared in two ways: first, between each homemade kefir group (whole milk and skim milk) and the standard dietary counseling group; second, between the homemade whole-milk kefir group and the homemade skim-milk kefir group. A positive change indicates an increase in bowel movement frequency, which is a better outcome. |
Baseline and 1 month (end of intervention)
|
|
Change from Baseline in Stool Consistency as Assessed by the Bristol Stool Form Scale at 1 Month
Prazo: Baseline and 1 month (end of intervention)
|
Participants recorded each bowel movement in a self-report diary. For the end-of-intervention value, the mean number of bowel movements per week was calculated from all diary records over the entire 1-month intervention period. The change from baseline (mean weekly frequency over the intervention period minus baseline frequency) was compared in two ways: first, between each homemade kefir group (whole milk and skim milk) and the standard dietary counseling group; second, between the homemade whole-milk kefir group and the homemade skim-milk kefir group. A positive change indicates an increase in bowel movement frequency, which is a better outcome. Unit of Measure: bowel movements per week |
Baseline and 1 month (end of intervention)
|
|
Change from Baseline in Health-Related Quality of Life as Assessed by the EQ-5D Index Score and EQ-5D Visual Analogue Scale (EQ VAS) at 1 Month
Prazo: Baseline and 1 month ( end of intervention)
|
Health-related quality of life was assessed with the EuroQol 5-Dimension, 3-Level questionnaire (EQ-5D-3L), which has two components. The descriptive system covers five dimensions (mobility, self-care, usual activities, pain/discomfort and anxiety/depression), each rated at three levels (no problems, some problems, extreme problems). Responses were converted into a single index score using the Chilean time trade-off value set (Zarate et al., 2011). The index ranges from [value of minimum; values below 0 represent health states considered worse to 1 maximum; full health. The visual analogue scale (EQ VAS) records self-rated health on the day of assessment, from 0 (minimum; worst imaginable health) to 100 (maximum; best imaginable health). For both components, higher scores indicate better health status. The change from baseline (score at the end of the intervention minus baseline) was compared for each component in two ways: first, between each homemade kefir |
Baseline and 1 month ( end of intervention)
|
|
Sensory Acceptability of Homemade Whole-Milk and Skim-Milk Kefir as Assessed by a 7-Point Hedonic Scale at 1 Month
Prazo: 1 month (end of intervention)
|
Sensory acceptability of the homemade kefir was assessed at the end of the intervention with a 7-point hedonic scale (Likert type) in participants allocated to the whole-milk or skim-milk kefir groups. Participants rated each sensory attribute (appearance, color, aroma, flavor, texture and overall acceptability) from 1 (minimum; dislike very much) to 7 (maximum; like very much), with 4 representing neither like nor dislike. Each attribute was scored separately. Higher scores indicate greater acceptability, which is a better outcome. The scores for each attribute were compared between the homemade whole-milk kefir group and the homemade skim-milk kefir group. Participants in the standard dietary counseling group did not consume kefir and were not assessed. Unit of Measure: score on a scale |
1 month (end of intervention)
|
|
Adherence to Homemade Kefir Consumption, Measured as the Percentage of Prescribed Daily Doses Consumed and Recorded in a Self-Report Log, Over 1 Month
Prazo: From day 1 to 1 month (entire intervention period)
|
Adherence was assessed in participants allocated to the whole-milk or skim-milk kefir groups using a self-report log. Each day, participants recorded whether the prescribed daily dose was consumed or not consumed. The prescribed dose escalated over the first three days (50 mL on day 1, 100 mL on day 2 and 150 mL on day 3) and was then 200 mL/day from day 4 until the end of the intervention. Adherence was calculated as the number of daily doses consumed divided by the total number of prescribed daily doses, multiplied by 100. Scores range from 0% (minimum) to 100% (maximum). Higher percentages indicate greater adherence, which is a better outcome. Adequate adherence was defined as consuming at least 80% of the prescribed daily doses. Adherence was compared between the homemade whole-milk kefir group and the homemade skim-milk kefir group. Participants in the standard dietary counseling group did not consume kefir and were not assessed. Unit percentage of prescribed daily doses |
From day 1 to 1 month (entire intervention period)
|
|
Incidence of adverse events
Prazo: Weekly, from day 1 to 1 month (entire intervention period)
|
Adverse events were recorded weekly throughout the intervention in participants allocated to the whole-milk or skim-milk kefir groups. Gastrointestinal adverse events included bloating, flatulence, abdominal pain or cramping, nausea and diarrhea. Any other adverse event reported by participants was also recorded. Each event was classified by severity (mild, moderate or severe) and by its relationship to kefir consumption (related or not related). The number and percentage of participants with at least one adverse event, overall, by type of event, by severity and by relationship to kefir, were compared between the homemade whole-milk kefir group and the homemade skim-milk kefir group. Adverse events were not recorded in the standard dietary counseling group, because its participants did not receive kefir. Unit of Measure: participants |
Weekly, from day 1 to 1 month (entire intervention period)
|
Colaboradores e Investigadores
Patrocinador
Patrocinador
Investigadores
Investigadores
- Investigador principal: CECILIA A SEPULVEDA, MAGISTER EN NUTRICION, Universidad Mayor
Publicações e links úteis
Publicações Gerais
- Mearin F, Lacy BE, Chang L, Chey WD, Lembo AJ, Simren M, Spiller R. Bowel Disorders. Gastroenterology. 2016 Feb 18:S0016-5085(16)00222-5. doi: 10.1053/j.gastro.2016.02.031. Online ahead of print.
- Turan I, Dedeli O, Bor S, Ilter T. Effects of a kefir supplement on symptoms, colonic transit, and bowel satisfaction score in patients with chronic constipation: a pilot study. Turk J Gastroenterol. 2014 Dec;25(6):650-6. doi: 10.5152/tjg.2014.6990.
- Bui G, Marco ML. Impact of Fermented Dairy on Gastrointestinal Health and Associated Biomarkers. Nutr Rev. 2026 Jun 1;84(6):1252-1274. doi: 10.1093/nutrit/nuaf114.
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Real)
Início do estudo
Conclusão Primária (Estimado)
Conclusão Primária
Conclusão do estudo (Estimado)
Conclusão do estudo
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Primeira postagem
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última Atualização Postada
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Última verificação
Mais Informações
Termos relacionados a este estudo
Palavras-chave
Termos MeSH relevantes adicionais
Outros números de identificação do estudo
Outros números de identificação do estudo
- 973/2026
- 0738 (Outro identificador: COMITE DE ETICA UNIVERSIDAD MAYOR)
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .